Dr Elena Castro is a Consultant Medical Oncologist at Hospital Universitario 12 de Octubre in Madrid, Spain.  She treats patients with advanced bladder and prostate cancer, most of them within the context of clinical trials. She studied medicine and obtained a PhD from the University of Salamanca, Spain.  After training in medical oncology, she completed a four-year fellowship in Cancer Genetics at the Institute of Cancer Research, UK.   Later, she joined the Spanish National Cancer Research Center as a clinician-scientist.  Her research has focused on addressing the clinical implications of genetic and genomic variants in prostate cancer, receiving several awards for her work. She has also authored numerous articles published in international peer-reviewed journals including some relevant papers on the impact of germline variants in prostate cancer.   

Dr Elena Castro has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bayer, Janssen, MSD, Novartis, Pfizer, Synlab and Telix.